176 related articles for article (PubMed ID: 29916057)
21. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.
Yazdanian M; Briggs K; Jankovsky C; Hawi A
Pharm Res; 2004 Feb; 21(2):293-9. PubMed ID: 15032311
[TBL] [Abstract][Full Text] [Related]
22. Investigation of Ethylene Oxide-co-propylene Oxide for Dissolution Enhancement of Hot-Melt Extruded Solid Dispersions.
Hurley D; Potter CB; Walker GM; Higginbotham CL
J Pharm Sci; 2018 May; 107(5):1372-1382. PubMed ID: 29410037
[TBL] [Abstract][Full Text] [Related]
23. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
24. Enhanced skin delivery of quercetin by microemulsion.
Kitagawa S; Tanaka Y; Tanaka M; Endo K; Yoshii A
J Pharm Pharmacol; 2009 Jul; 61(7):855-60. PubMed ID: 19589226
[TBL] [Abstract][Full Text] [Related]
25. Potential of Excipient Emulsions for Improving Quercetin Bioaccessibility and Antioxidant Activity: An in Vitro Study.
Chen X; Zou L; Liu W; McClements DJ
J Agric Food Chem; 2016 May; 64(18):3653-60. PubMed ID: 27136205
[TBL] [Abstract][Full Text] [Related]
26. Rutin-phospholipid complex: an innovative technique in novel drug delivery system- NDDS.
Singh D; Rawat MS; Semalty A; Semalty M
Curr Drug Deliv; 2012 May; 9(3):305-14. PubMed ID: 22283645
[TBL] [Abstract][Full Text] [Related]
27. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates.
Kim MK; Park KS; Yeo WS; Choo H; Chong Y
Bioorg Med Chem; 2009 Feb; 17(3):1164-71. PubMed ID: 19128975
[TBL] [Abstract][Full Text] [Related]
28. Increase of rutin antioxidant activity by generating Maillard reaction products with lysine.
Zhang R; Zhang BL; He T; Yi T; Yang JP; He B
Bioorg Med Chem Lett; 2016 Jun; 26(11):2680-4. PubMed ID: 27106712
[TBL] [Abstract][Full Text] [Related]
29. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
Widanapathirana L; Tale S; Reineke TM
Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
[TBL] [Abstract][Full Text] [Related]
30. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
[TBL] [Abstract][Full Text] [Related]
31. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
32. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide.
Markovic M; Zur M; Ragatsky I; Cvijić S; Dahan A
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276565
[TBL] [Abstract][Full Text] [Related]
33. Nano-lipid Complex of Rutin: Development, Characterisation and In Vivo Investigation of Hepatoprotective, Antioxidant Activity and Bioavailability Study in Rats.
Ravi GS; Charyulu RN; Dubey A; Prabhu P; Hebbar S; Mathias AC
AAPS PharmSciTech; 2018 Nov; 19(8):3631-3649. PubMed ID: 30280357
[TBL] [Abstract][Full Text] [Related]
34. Permeation and skin retention of quercetin from microemulsions containing Transcutol® P.
Censi R; Martena V; Hoti E; Malaj L; Di Martino P
Drug Dev Ind Pharm; 2012 Sep; 38(9):1128-33. PubMed ID: 22188183
[TBL] [Abstract][Full Text] [Related]
35. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
36. Absorption of bendazac lysine after topical application to the rabbit eye.
Valeri P; Palmery M; Martinelli B; Catanese B
Pharmacol Res Commun; 1987 Aug; 19(8):517-25. PubMed ID: 3432319
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a new solid non-aqueous self-double-emulsifying drug-delivery system for topical application of quercetin.
Wang Q; Hu C; Zhang H; Zhang Y; Liu T; Qian A; Xia Q
J Microencapsul; 2016 Dec; 33(8):785-794. PubMed ID: 27875065
[TBL] [Abstract][Full Text] [Related]
38. Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles.
Romanelli L; Valeri P; Morrone LA; Pimpinella G; Graziani G; Tita B
Life Sci; 1994; 54(13):877-85. PubMed ID: 8139376
[TBL] [Abstract][Full Text] [Related]
39. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
[TBL] [Abstract][Full Text] [Related]
40. Absorption and urinary excretion of quercetin, rutin, and alphaG-rutin, a water soluble flavonoid, in rats.
Shimoi K; Yoshizumi K; Kido T; Usui Y; Yumoto T
J Agric Food Chem; 2003 Apr; 51(9):2785-9. PubMed ID: 12696973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
